PE20060768A1 - Composicion farmaceutica que comprende hidroclorotiazida y telmisartano - Google Patents
Composicion farmaceutica que comprende hidroclorotiazida y telmisartanoInfo
- Publication number
- PE20060768A1 PE20060768A1 PE2005001465A PE2005001465A PE20060768A1 PE 20060768 A1 PE20060768 A1 PE 20060768A1 PE 2005001465 A PE2005001465 A PE 2005001465A PE 2005001465 A PE2005001465 A PE 2005001465A PE 20060768 A1 PE20060768 A1 PE 20060768A1
- Authority
- PE
- Peru
- Prior art keywords
- pharmaceutical composition
- hydrochlorothiazide
- composition including
- telmisartane
- composition
- Prior art date
Links
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 title abstract 3
- 229960002003 hydrochlorothiazide Drugs 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 abstract 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 abstract 3
- 239000005537 C09CA07 - Telmisartan Substances 0.000 abstract 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 229960005187 telmisartan Drugs 0.000 abstract 2
- 206010007559 Cardiac failure congestive Diseases 0.000 abstract 1
- 229920002261 Corn starch Polymers 0.000 abstract 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 abstract 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 206010022489 Insulin Resistance Diseases 0.000 abstract 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 abstract 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 abstract 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 abstract 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 abstract 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 abstract 1
- 229940126317 angiotensin II receptor antagonist Drugs 0.000 abstract 1
- 210000004556 brain Anatomy 0.000 abstract 1
- 239000008120 corn starch Substances 0.000 abstract 1
- 239000002934 diuretic Substances 0.000 abstract 1
- 230000001882 diuretic effect Effects 0.000 abstract 1
- 239000008101 lactose Substances 0.000 abstract 1
- 235000019359 magnesium stearate Nutrition 0.000 abstract 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 abstract 1
- 239000008108 microcrystalline cellulose Substances 0.000 abstract 1
- 229940016286 microcrystalline cellulose Drugs 0.000 abstract 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 abstract 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 abstract 1
- 229940069328 povidone Drugs 0.000 abstract 1
- 239000000600 sorbitol Substances 0.000 abstract 1
- 235000010356 sorbitol Nutrition 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
- 230000002792 vascular Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63706204P | 2004-12-17 | 2004-12-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20060768A1 true PE20060768A1 (es) | 2006-09-29 |
Family
ID=35589356
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2005001465A PE20060768A1 (es) | 2004-12-17 | 2005-12-15 | Composicion farmaceutica que comprende hidroclorotiazida y telmisartano |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP1827424A1 (enExample) |
| JP (1) | JP2008524136A (enExample) |
| KR (1) | KR20070097511A (enExample) |
| CN (1) | CN101080225A (enExample) |
| AR (1) | AR052052A1 (enExample) |
| AU (1) | AU2005315855A1 (enExample) |
| BR (1) | BRPI0519656A2 (enExample) |
| CA (1) | CA2589493A1 (enExample) |
| EA (1) | EA200701159A1 (enExample) |
| IL (1) | IL183944A0 (enExample) |
| NO (1) | NO20072325L (enExample) |
| PE (1) | PE20060768A1 (enExample) |
| TW (1) | TW200637546A (enExample) |
| UY (1) | UY29274A1 (enExample) |
| WO (1) | WO2006063737A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7232828B2 (en) | 2002-08-10 | 2007-06-19 | Bethesda Pharmaceuticals, Inc. | PPAR Ligands that do not cause fluid retention, edema or congestive heart failure |
| US8637078B2 (en) * | 2005-11-24 | 2014-01-28 | Boehringer Ingelheim International Gmbh | Bilayer tablet comprising telmisartan and diuretic |
| EP1970053A1 (en) * | 2007-03-14 | 2008-09-17 | Boehringer Ingelheim Pharma GmbH & Co. KG | Pharmaceutical composition |
| CA2702904A1 (en) † | 2007-10-19 | 2009-04-23 | Otsuka Pharmaceutical Co., Ltd. | Matrix-type pharmaceutical solid preparation |
| EP2203158A4 (en) | 2007-10-30 | 2012-12-26 | Reddys Lab Ltd Dr | PHARMACEUTICAL FORMULATIONS WITH TELMISARTAN AND HYDROCHLORTHIAZIDE |
| US20110008428A1 (en) | 2008-03-19 | 2011-01-13 | Ratiopharm Gmbh | Solid pharmaceutical composition comprising a non-peptide angiotensin ii receptor antagonist and a diuretic |
| BRPI0916847A2 (pt) * | 2008-07-31 | 2016-02-10 | Takeda Pharmaceutical | preparação sólida, e, métodos para estabilizar um composto e para melhorar a propriedade de dissolução de um composto. |
| GB0822170D0 (en) * | 2008-12-04 | 2009-01-14 | Arrow Int Ltd | Telmisartan with diuretic formulations |
| SI2443094T1 (sl) | 2009-06-19 | 2013-08-30 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Postopek za pripravo telmisartana |
| EP2448575A2 (en) * | 2009-07-02 | 2012-05-09 | Bilgic Mahmut | Pharmaceutical composition increasing solubility and stability |
| WO2011002423A2 (en) * | 2009-07-02 | 2011-01-06 | Mahmut Bilgic | Solubility enhancing pharmaceutical composition |
| TR200906506A2 (tr) | 2009-08-24 | 2011-03-21 | Bi̇lgi̇ç Mahmut | Telmisartan içeren katı dozaj formları. |
| WO2011161123A2 (en) | 2010-06-21 | 2011-12-29 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Multilayer pharmaceutical tablet comprising telmisartan and a diuretic |
| WO2014119767A1 (ja) * | 2013-01-31 | 2014-08-07 | 沢井製薬株式会社 | テルミサルタンとヒドロクロロチアジドとを含有する多層錠剤 |
| JP6422868B2 (ja) * | 2013-07-23 | 2018-11-14 | 第一三共株式会社 | 高血圧症の予防又は治療のための医薬 |
| CN106562973A (zh) * | 2016-11-06 | 2017-04-19 | 成都先先先生物科技有限公司 | 一种抗高血压药物复方制剂 |
| CN107501192A (zh) * | 2017-08-15 | 2017-12-22 | 中国科学院上海药物研究所 | 替米沙坦与氢氯噻嗪的共晶 |
| CN108653227A (zh) * | 2018-08-09 | 2018-10-16 | 湖北舒邦药业有限公司 | 一种替米沙坦氢氯噻嗪片及其制备方法 |
| EP4029867A1 (en) * | 2021-01-13 | 2022-07-20 | Alpha Cognition Inc. | Solid forms of galantamine benzoate gluconate |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4229085C2 (de) * | 1992-09-01 | 1996-07-11 | Boehringer Mannheim Gmbh | Längliche, teilbare Tablette |
| KR100876302B1 (ko) * | 2002-01-16 | 2008-12-31 | 베링거 잉겔하임 파르마 게엠베하 운트 코 카게 | 사실상 비결정질 형태인 텔미사르탄의 제조방법 |
-
2005
- 2005-12-09 CA CA002589493A patent/CA2589493A1/en not_active Abandoned
- 2005-12-09 BR BRPI0519656-6A patent/BRPI0519656A2/pt not_active Application Discontinuation
- 2005-12-09 JP JP2007545905A patent/JP2008524136A/ja active Pending
- 2005-12-09 EP EP05814002A patent/EP1827424A1/en not_active Withdrawn
- 2005-12-09 EA EA200701159A patent/EA200701159A1/ru unknown
- 2005-12-09 CN CNA2005800434334A patent/CN101080225A/zh active Pending
- 2005-12-09 AU AU2005315855A patent/AU2005315855A1/en not_active Abandoned
- 2005-12-09 KR KR1020077016354A patent/KR20070097511A/ko not_active Withdrawn
- 2005-12-09 WO PCT/EP2005/013224 patent/WO2006063737A1/en not_active Ceased
- 2005-12-15 PE PE2005001465A patent/PE20060768A1/es not_active Application Discontinuation
- 2005-12-16 TW TW094144909A patent/TW200637546A/zh unknown
- 2005-12-16 AR ARP050105303A patent/AR052052A1/es unknown
- 2005-12-20 UY UY29274A patent/UY29274A1/es not_active Application Discontinuation
-
2007
- 2007-05-04 NO NO20072325A patent/NO20072325L/no not_active Application Discontinuation
- 2007-06-14 IL IL183944A patent/IL183944A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2005315855A1 (en) | 2006-06-22 |
| EP1827424A1 (en) | 2007-09-05 |
| IL183944A0 (en) | 2007-10-31 |
| WO2006063737A1 (en) | 2006-06-22 |
| KR20070097511A (ko) | 2007-10-04 |
| EA200701159A1 (ru) | 2007-12-28 |
| CN101080225A (zh) | 2007-11-28 |
| NO20072325L (no) | 2007-07-06 |
| JP2008524136A (ja) | 2008-07-10 |
| CA2589493A1 (en) | 2006-06-22 |
| TW200637546A (en) | 2006-11-01 |
| BRPI0519656A2 (pt) | 2009-03-03 |
| AR052052A1 (es) | 2007-02-28 |
| UY29274A1 (es) | 2006-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20060768A1 (es) | Composicion farmaceutica que comprende hidroclorotiazida y telmisartano | |
| CL2008003595A1 (es) | Compuestos heterociclicos nitrogenados, antagonistas del receptor de taquiquinina; agente farmaceutico que comprende el compuesto; y uso en la profilaxis o el tratamiento de una enfermedad del tracto urinario inferior, una enfermedad gastrointestinal o una enfermedad del sistema nervioso central. | |
| UA86831C2 (uk) | Композиція таблетки пролонгованого вивільнення, яка містить праміпексол або його фармацевтично прийнятну сіль, спосіб її виготовлення та її застосування | |
| BRPI0507887A (pt) | comprimido de múltiplas camadas | |
| EA200400879A1 (ru) | Двухслойная фармацевтическая таблетка, содержащая телмисартан и диуретик, и её получение | |
| DOP2004000907A (es) | Procedimientos y composiciones farmaceuticas para tratar aterosclerosis dislipidemias y afecciones relacionadas | |
| MX2020002841A (es) | Formulacion de valbenazina de alta dosis y composiciones, metodos y kits relacionados con la misma. | |
| GT200800060A (es) | Derivados de espiro aza-sustituidos | |
| PE20020082A1 (es) | Composicion farmaceutica que comprende un inhibidor de aldosterona-sintasa y un antagonista del receptor de angiotensina ii (at1) | |
| NZ593045A (en) | Pharmaceutical dosage form comprising nifedipine or nisoldipine and an angiotensin-ii antagonist and/or a diuretic | |
| CL2008001946A1 (es) | Compuestos derivados de imidazol, antagonistas de receptores ccr2, ccr3, ccr5; procedimiento de preparacion; y uso en el tratamiento de enfermedades vasculares perifericas. | |
| AR069031A1 (es) | Composicion | |
| MY145089A (en) | Pharmaceutical composition | |
| AR067077A1 (es) | Preparado solido farmaceutico y metodo de produccion del mismo | |
| AR061233A1 (es) | Formulacion de liberacion prolongada de naltrexona | |
| PE20020617A1 (es) | Composicion que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina o un sensibilizante a la insulina | |
| PE20120421A1 (es) | Composicion farmaceutica que comprende aleglitazar | |
| CY1113484T1 (el) | Ενωση 3-φαινυλπυραζολο[5,1-b]θειαζολιου | |
| ATE415947T1 (de) | Verwendung von stärke mit abgespaltenen seitenketten in der extrudierung / spheronisierung von pharmazeutischen pellets | |
| TR200604349A2 (tr) | Aripiprazol içeren farmasötik bileşimler | |
| AR063255A1 (es) | Formulacion de comprimido farmaceutico | |
| MX2007013468A (es) | Composiciones que contienen tanaproget micronizado. | |
| PE20121404A1 (es) | Formulacion de liberacion controlada de carvedilol | |
| PE20110412A1 (es) | Formulacion farmaceutica de eprosartan | |
| PE20081364A1 (es) | Composicion farmaceutica que comprende valsartan |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |